ΒΙΟΓΡΑΦΙΚΟ ΣΗΜΕΙΩΜΑ (CV)

ΠΑΠΑΔΟΠΟΥΛΟΥ ΛΕΥΚΟΘΕΑΣΕΜΠΕΙΡΙΑ

ΠΡΟΣΩΠΙΚΑ ΣΤΟΙΧΕΙΑ Ονοματεπώνυμο Παπαδοπούλου Λευκοθέα

Διεύθυνση Κατοικίας 28ης Οκτωβρίου 18, Θεσσαλονίκη, ΤΚ 54642

Τηλέφωνα επικοινωνίας 2310-997636 (Τμήμα Φαρμακευτικής, ΑΠΘ)

Διεύθυνση Ηλεκτρονικού Ταχυδρομείου lefkotea@pharm.auth.gr

ΕΚΠΑΙΔΕΥΣΗ Πτυχίο Διδακτορικό

Τμήμα Φαρμακευτικής, Α.Π.Θ. 1980

Φαρμακολογία, Τμήμα Φαρμακευτικής, Α.Π.Θ., 1991

ΕΠΑΓΓΕΛΜΑΤΙΚΗ ΔΙΑΔΡΟΜΗ 1982 Διορισμός ως «Επιστημονικός Συνεργάτης» στο Τμήμα Φαρμακευτικής, ΑΠΘ 1993 Εκλογή σε θέση Λέκτορα, Τμήμα Φαρμακευτικής, ΑΠΘ 2004 Εκλογή σε θέση Επίκουρου Καθηγητή, Τμήμα Φαρμακευτικής, ΑΠΘ 2012 Εκλογή σε θέση Αναπληρωτή Καθηγητή, Τμήμα Φαρμακευτικής, ΑΠΘΕ

ΕΠΙΣΤΗΜΟΝΙΚΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ - ΕΠΙΤΕΥΓΜΑΤΑ Εκπαιδευτική άδεια ως Post-Doctoral Research Fellow Απρίλιος 1996 -Νοέμβριος 1997 (20 μήνες) Department of Neurology, Ιούλιος 1998- Σεπτέμβριος 1998 ( 3 μήνες) College of Physicians and Surgeons, COLUMBIA UNIVERSITY in the City of New York, U.S.A.

AΠΟΜΟΝΩΣΗ ΚΑΙ ΤΑΥΤΟΠΟΙΗΣΗ ΤΟΥ ΑΝΘΡΩΠΙΝΟΥ SCO2 ΓΟΝΙΔΙΟΥ. Papadopoulou LC, et al (1999) Fatal infantile cardioencephalomyopathy with COX deficiency and

mutations in SCO2, a COX assembly gene. Nature Genetics, 23(3):333-337 ΚKατάθεση σε βάσεις δεδομένων:

Nucleotide: GenBank Accession number: F177385

P Protein: GenBank Accession number: OMIM:

AAF05313 ##604377

PATENT pending - 2019

9389GR,

Κατάθεση αίτησης σε Εθνικό επίπεδο 20190100504 ΑΠΘ-ΕΛΚΕ, ΠΘ-ΕΛΚΕ,

“Μέθοδος για την ανάπτυξη μιας πλατφόρμας ενδοκυττάριας μεταφοράς θεραπευτικών IVT-mRNAs”.

ΚΥΡΙΑ ΕΡΕΥΝΗΤΙΚΑ ΕΝΔΙΑΦΕΡΟΝΤΑ Αλληλεπιδράσεις φαρμάκων και μοριακοί μηχανισμοί φαρμακολογικής και τοξικής δράσης

Κλωνοποίηση και έκφραση πυρηνικών γονιδίων σε βακτηριακά κύτταρα

Bιοτεχνολογική παραγωγή ανασυνδυασμένων πρωτεϊνών

Ενδοκυτταρική μεταφορά ανθρώπινων ανασυνδυασμένων πρωτεϊνών μέσω της χρήσης της τεχνολογίας της Πρωτεϊνικής Μεταγωγής (PTD Τεχνολογία), με απώτερο στόχο την «πρωτεϊνική θεραπεία» μονογονιδιακών ασθενειών (μιτοχονδριακές ασθένειες – αιμοσφαιρινοπάθειες - θαλασσαιμίες)

Ραδιοεπισήμανση ενώσεων και ανασυνδυασμένων πρωτεϊνών και μελέτη της βιοκατανομής τους σε πειραματόζωα

Aξιολόγηση βιοενεργητικής (cell bioenergetics) σε κυτταρικές καρκινικές σειρές - ρόλος σηματοδοτικών μονοπατιών στην παθογένεια του καρκίνου

Ανάπτυξη IVT-mRNAs, μέσω της PTD Τεχνολογίας, ως θεραπευτικών μορίων σε μονογονιδιακές-μεταβολικές ασθένειες

Ανοσοθεραπεία του καρκίνου - CAR T Θεραπεία

ΕΚΠΑΙΔΕΥΤΙΚΟ ΕΡΓΟ - ΤΜΗΜΑ ΦΑΡΜΑΚΕΥΤΙΚΗΣ ΠΡΟΠΤΥΧΙΑΚΕΣ ΣΠΟΥΔΕΣ

ΔΙΔΑΣΚΑΛΙΑ

Τοξικολογία 1999 -

Κλινική Φαρμακολογία και Θεραπευτική 1999 -

Φαρμακολογία ΙΙ 2015 - 2018

Φαρμακευτική Βιοτεχνολογία 2015 - 2018

Φαρμακολογία Ι 2018- “ΑΡΙΣΤΕΙΑ στη ΔΙΔΑΣΚΑΛΙΑ”, Σχολή Επιστημών Υγείας, Α.Π.Θ., Ακαδημαϊκό έτος: 2014-2015 ΜΕΤΑΠΤΥΧΙΑΚΕΣ ΣΠΟΥΔΕΣ

ΔΙΔΑΣΚΑΛΙΑ

Βιοπληροφορική / Εφαρμογές Η/Υ στη Μοριακή Βιολογία και Βιοτεχνολογία

Φαρμακευτική Βιοτεχνολογία ΙΙ / Τεχνολογίες Παραγωγής ουσιών Φαρμακευτικού και Διαγνωστικού Ενδιαφέροντος με Γενετική Μηχανική

ΕΠΙΣΤΗΜΟΝΙΚΗ ΥΠΕΥΘΥΝΟΣ της κατεύθυνσης «Φαρμακολογία και Θεραπευτική», 2015-2020

Επίσης,

Συμμετέχω στη διδασκαλία

1. του ΠΜΣ «Βιομηχανική Φαρμακευτική» του Τμήματος Φαρμακευτικής, ΑΠΘ, Ε.Υ.

Αναπληρώτρια καθηγήτρια, κ. Αικατερίνη Μαρκοπούλου 2020-

2. του ΠΜΣ «Τοξικολογία» του Τμήματος Βιοχημεία & Βιοτεχνολογία, του Πανεπιστημίου

Θεσσαλίας, Ε.Υ. Καθηγητής κ. Δημήτριος Κουρέτας, 2018-

3. του ΔΠΜΣ του Τμήματος Ιατρικής του Δημοκρίτειου Πανεπιστημίου Θράκης, σε συνεργασία με

το Τμήμα Βιοϊατρικών Επιστημών του Διεθνούς Πανεπιστημίου Ελλάδας με τίτλο: «Βιο-Ιατρικές

και Μοριακές Επιστήμες στη Διάγνωση και Θεραπεία Ασθενειών», Ε.Υ.: καθηγητής κ. Θεόδωρος

Λιαλιάρης 2016-

ΕΡΕΥΝΗΤΙΚΟ ΕΡΓΟ

C CITATIONS: 1445 (Google Scholar), Index: h: 12, i10: 14

https://scholar.google.com/citations?view_op=new_articles&hl=el&imq=Papadopoulou+LC https://www.ncbi.nlm.nih.gov/pubmed/?term=Papadopoulou+LC

https://orcid.org/0000-0002-5738-969X ΙΣΤΟΣΕΛΙΔΑ: http://www.pharm.auth.gr/el/faculty/45

ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ ΑΝΑΛΥΣΗ ΤΩΝ ΑΛΛΗΛΕΠΙΔΡΑΣΕΩΝ ΑΝΘΡΑΚΥΚΛΙΝΩΝ -ΣΙΔΗΡΟΠΟΡΦΥΡΙΝΩΝ

ΣΤΟ ΑΙΜΟΠΟΙΗΤΙΚΟ ΣΥΣΤΗΜΑ

Δημοσίευση σε βιβλίο Miliotou, AN and Papadopoulou LC. (2020) In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development”. In: Swiech K., Malmegrim K., Picanço-Castro V. (eds). Chimeric Antigen Receptor T Cells. Methods in Molecular Biology, Humana, New York, NY, Volume 2086, Pages 87-117, 2020, Nov. DOI: 10.1007/978-1-0716-0146-4_7

ΕΠΙΣΤΗΜΟΝΙΚΑ ΑΡΘΡΑ (Scientific papers) 1. Vizirianakis IS, Miliotou, A.N., Mystridis GA, Andriotis, EG, Andreadis I, Papadopoulou LC,

Fatouros DG. (2019) Tackling pharmacological response heterogeneity by PBPK modeling to advance precision medicine productivity of nanotechnology and genomics therapeutics. Submitted for publication. Expert Review of Precision Medicine and Drug Development 4(3), 139-151.

2. Haido-Christina Pagoni, Stella Xylouri, Georgios Kaiafas, Marialena Lazou, Georgia Bombola, Lefkothea Papadopoulou, Georgios Psomas and Dionysia Papagiannopoulou. (2019) Synthesis and biological evaluation of organometallic rhenium tricarbonyl fluoroquinolones with increased cytotoxicity against myeloid leukemia K-562 cells. J Biol Inorg Chem. 24(5):609-619.

3. Miliotou NA, Papadopoulou LC. (2018) CAR T-cell Therapy: A New Era in Cancer

Immunotherapy. Curr Pharm Biotechnol., 19(1):5-18. (INVITED review).

4. Papadopoulou LC, Ingendoh-Tsakmakidis A, Mpoutoureli CN, Tzikalou LD, Spyridou ED, Gavriilidis GI, Kaiafas GC, Ntaska AT, Vlachaki E, Panayotou G, Samiotaki M, Tsiftsoglou AS. (2018) Production and Transduction of a Human Recombinant β-Globin Chain into Proerythroid K-562 Cells To Replace Missing Endogenous β-Globin. Mol Pharm. 3;15(12):5665-5677.

5. Kydonaki TE, Tsoukas E, Mendes F, Hatzidimitriou AG, Paulo A, Papadopoulou LC, Papagiannopoulou D, Psomas G. (2016) Synthesis, characterization and biological evaluation of (99m)Tc/Re-tricarbonyl quinolone complexes. J Inorg Biochem., 160:94-105.

6. Papadopoulou LC, Kyriazou ΑV, Bonovolias ID and Tsiftsoglou AS (2014) Imatinib inhibits the expression of SCO2 and FRATAXIN genes that encode mitochondrial proteins in human Bcr–Abl+ leukemia cells. Blood Cells, Molecules and Diseases, 53(1-2): 84-90.

7. Papadopoulou LC, Tsiftsoglou AS. (2013) The Potential Role of Cell Penetrating Peptides in the Intracellular Delivery of Proteins for Therapy of Erythroid Related Disorders. Pharmaceuticals 6, 32-53. (INVITED review).

8. Papadopoulou LC, Tsiftsoglou AS. (2011) Transduction of human recombinant proteins into

mitochondria as a protein therapeutic approach for mitochondrial disorders. Pharm Res. Nov;28(11):2639-56. (INVITED review).

9. Foltopoulou PF, Tsiftsoglou AS, Bonovolias ID, Ingendoh AT, Papadopoulou LC. (2010) Intracellular delivery of full length recombinant human mitochondrial L-Sco2 protein into the mitochondria of permanent cell lines and SCO2 deficient patient's primary cells. Biochim Biophys Acta. Jun;1802(6):497-508.

10. Bonovolias ID., Papadopoulou L.C. and Tsiftsoglou A.S. (2010) Assessing the effect of Imatinib

on the expression of genes involved in mitochondrial cell respiration in human K-562 CML cells. Review of Clinical Pharmacology and Pharmacokinetics (Epitheorese Klinikes Farmakologias and Farmakokinetikes), International Edition, 24: 123-124.

11. Papadopoulou LC, Foltopoulou P.F., Tsiftsoglou AS (2010) Intracellular Delivery of Recombinant Human Proteins into Mammalian cells as a Potential Therapeutic Approach. 10th European Biological Inorganic Chemistry Conference (Eurobic10) Pages: 23-28

12. Zaverda C.G., Nentoudi K.A., Foltopoulou P.F., Tsiftsoglou A.S. and Papadopoulou L.C. (2007)

Bacterial production of recombinant human β-globin-TAT-HA peptide intended for targeted delivery in thalassemic cells. Proceedings of The International Conference on Nanomedicine, September 9-11, Chalkidiki, Greece, pp. 202-209

13. Papadopoulou L.C, Tsiftsoglou A.S., and Foltopoulou P.F. (2007) PTD-technology

complemented by combinatorial tag-cloning for bacterial production of recombinant human proteins intended for intracellular delivery. Proceedings of The International Conference on Nanomedicine, September 9-11, Chalkidiki, Greece, pp. 210-217

14. Tsiftsoglou AS, Tsamadou AI, Papadopoulou LC. (2006) Heme as key regulator of major

mammalian cellular functions: molecular, cellular, and pharmacological aspects. Pharmacol Ther. Aug;111(2):327-45. (INVITED review).

15. Foltopoulou P.F., Tsiftsoglou A.S. and Papadopoulou L.C. (2005). Production of genetically

engineered TAT-Sco2 protein aimed for intracellular delivery into mitochondria: Implications to the therapy of COX-deficient fatal infantile cardioencephalopathy. Review of Clinical Pharmacology and Pharmacokinetics (Epitheorese Klinikes Farmakologias and Farmakokinetikes), Greek Edition, 23 (1): 106-107

16. Foltopoulou PF, Zachariadis GA, Politou AS, Tsiftsoglou AS, Papadopoulou LC. (2004) Human recombinant mutated forms of the mitochondrial COX assembly Sco2 protein differ from wild-type in physical state and copper binding capacity. Mol Genet Metab. Mar;81(3):225-36.

17. Clark KM, Brown TA, Davidson MM, Papadopoulou LC, Clayton DA. (2002) Differences in nuclear gene expression between cells containing monomer and dimer mitochondrial genomes. Gene. Mar 6;286(1):91-104.

18. Sue CM, Karadimas C, Checcarelli N, Tanji K, Papadopoulou LC, Pallotti F, Guo FL, Shanske S,

Hirano M, De Vivo DC, Van Coster R, Kaplan P, Bonilla E, DiMauro S. (2000) Differential features of patients with mutations in two COX assembly genes, SURF-1 and SCO2. Ann Neurol. May;47(5):589-95.

19. Papadopoulou L.C., Foltopoulou P.F., Tsiftsoglou A.S., Sue C.M., Tanji K., Bonilla E., Hirano M.,

DiMauro S. and Schon E.A. (2000). Mutations in Human SCO2, a nuclear COX assembly gene, and their possible role in causing COX deficiency associated with fatal cardioencephalomyopathy. Newsletter, 47:111-112.

20. Papadopoulou LC, Sue CM, Davidson MM, Tanji K, Nishino I, Sadlock JE, Krishna S, Walker W,

Selby J, Glerum DM, Coster RV, Lyon G, Scalais E, Lebel R, Kaplan P, Shanske S, De Vivo DC, Bonilla E, Hirano M, DiMauro S, Schon EA. (1999) Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. Nature Genetics Nov;23(3):333-7.

21. Papadopoulou LC, Theophilidis G, Thomopoulos GN, Tsiftsoglou AS. (1999) Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression. Biochem Pharmacol. Mar 1;57(5):481-9.

22. Manfredi G, Thyagarajan D, Papadopoulou LC, Pallotti F, Schon EA. (1997) The fate of human sperm-derived mtDNA in somatic cells. Am J Hum Genet. Oct;61(4):953-60.

23. Papadopoulou LC, Tsiftsoglou AS. (1996) Effects of hemin on apoptosis, suppression of

cytochrome c oxidase gene expression, and bone-marrow toxicity induced by doxorubicin (adriamycin). Biochem Pharmacol. Sep 13;52(5):713-22.

24. Papadopoulou LC, Tsiftsoglou AS. (1993). Mitochondrial cytochrome c oxidase as a target site

for daunomycin in K-562 cells and heart tissue. Cancer Res. 1993 Mar 1;53(5):1072-8. 25. Papadopoulou L.C. and Tsiftsoglou A.S (1993) Interactions of hemin and anthracyclines with

mitochondrial cytochrome c oxidase. J. Chemotherapy 5, Suppl. 1 May, 788-789. 26. Papadopoulou LC, Wheeler C, Tsiftsoglou AS. (1989) Possible role of mitochondrial

components in adriamycin-induced cytotoxicity of human leukemia cells. J Chemother. 1989 Jul;1(4 Suppl):1151-4.

27. Papadopoulou L.C., Wheeler C. and Tsiftsoglou A.S. (1988). Daunomycin-hemin interactions:

implications into the mechanism(s) of molecular action of anthracyclines on hemopoietic cells and therapeutic significance. Newsletter, 27: 15-18.

Abstracts

1. Papadopoulou L.C. and Tsiftsoglou A.S. (1989). Mitochondrial hemoproteins as target sites

involved in cytotoxic action of daunomycin in dividing and nondividing cells. Proc. Amer. Assoc. Cancer Res., 30: 561 (2234).

2. Vizirianakis I.S., Marcopoulou C., Kountourelis J.E., Papadopoulou L.C. and Tsiftsoglou A.S. (1990). RNA methylation as a key-regulatory process in growth and differentiation of murine erythroleukemia (MEL) cells: inhibition by N6-methyl-adenosine (N6meAdo). Proc. Amer. Assoc. Cancer Res., 31:35 (206).

3. Papadopoulou L.C., Oikonomou-Antoniadou M. and Tsiftsoglou A.S. (1990). Analysis of protective effects of hemin on adriamycin induced myelossuppression in rats. J. Cancer Res.Clin. Oncol., 116 (Suppl., part I): 481 (A4.129.05).

4. Papadopoulou L.C. and Tsiftsoglou A.S. (1994). Hemin selectively prevents apoptosis and partially reverses suppression of cytochrome c oxidase gene expression induced by adriamycin in human leukemia K-562 cells. Thirteenth meeting of the European Association for Cancer Research, Berlin, Germany, September 25-28, p 133.

5. Tsiftsoglou A.S., Papadopoulou L.C., Robinson S.H. and Wong W. (1995). Mechanisms by

which hemin counteracts adriamycin-induced myelossuppression. The International Symposium on porphyrias and heme related disorders, June 28-July 2. The Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 55 (Suppl.223): No 40.

6. Papadopoulou L.C., Sue C.M., Davidson M., Tanji K., Nishino I., Shanske S., DeVivo D.C., Bonilla E., Hirano M., DiMauro S. and Schon E.A. (1999). Mutations in a human COX assembly gene are associated with fatal cardioencephalomyopathy and COX deficiency. The Fourth Meeting on Mitochondrial Pathology, Queens' College, Cambridge, U.K., 16-19 September, p. 167.

7. Glerum D.M., Papadopoulou L., Schon E. and Adams D. (1999). Characterization of hSCO2

mutations involved in cytochrome oxidase deficiency. In American Journal of Human Genetics (October) Vol. 65, No. 4, pp. A236. 5720 South Woodlawn Ave, Chicago, Il 60637-1603 USA: Univ Chicago Press.

8. CM Sue, CL Karadimas, N Checarelli, K Tanji, LC Papadopoulou, F Pallotti, S Shanske, M Hirano, DC De Vivo, R Van Coster, P Kaplan, E Bonilla, S Di-Mauro. (2000) Comparison of clinical features in patients with COX assembly gene mutations. Neurology 54 (7): A388 Suppl., 3 APR 11

9. Tsiftsoglou A.S., Pappas I., Vizirianakis I., Sidiropoulou A. and Papadopoulou L.C. (2001).

Μechanisms of differentiation and differentiation dependent – apoptosis (DDA) in Leukemic cells. Oncology Research, 12: 273.

10. Foltopoulou P.F., Zachariadis G.., Tsiftsoglou A.S. and Papadopoulou L.C. (2002). Cloning, expression and purification of the mitochondrial assembly protein Sco2, involved in the pathogenesis of fatal infantile cardioencephalomyopathy. Epitheorese Klinikes Farmakologias and Farmakokinetikes, International Edition, 16: 66.

11. Zaverda C.G., Foltopoulou P.F., Tsiftsoglou A.S. and Papadopoulou L.C. (2005)

Biotechnological production of human fused recombinant β-globin-TAT protein for intracellular delivery in K562 cells: Alternative therapeutic approach of patients with βΟ–thalassemia. 12th Panhellenic Pharmaceutical Congress, Athens, 14-16 May, 37:083

12. Foltopoulou P., Zaverda C., Nentoudi K., Tsiftsoglou A. and Papadopoulou L. (2006) Production of human recombinant proteins Sco2 and beta-globin fused with PTDs for intracellular targeting delivery. 31st FEBS Congress in “Molecules in Health and Disease”, June 24-29, Instanbul, p370, PP-791a.

13. Kyriakidou H., Cieslak D., Papadopoulou L., Tsiftsoglou A., and Lazou A. (2006) Evaluation of

Doxorubicin-induced apoptosis in HepG2 cells. Hellenic Society for Biological Sciences. Proceedings of 28th Scientific Conference, Ioannina, May, p.184.

14. Foltopoulou P.F., Nentoudi K.A., Zaverda C.G., Tsiftsoglou A.S. and Papadopoulou L.C. (2006). Human recombinant proteins developed via combinatorial cloning and protein transduction technology (PTD) are intended for intracellular delivery and protein therapy of metabolic disorders. 11th International Conference on “Differentiation Therapy and Innovative Therapeutics in Oncology”, November 4-8, Versailles, France, p.42, P29.

15. Μarkou T., Iordanidou A., Cieslak D., Papadopoulou L., Tsiftsoglou A., and Lazou A. (2008).

Role of PI-3-K/GSK3 and MAPK signaling in doxorubicin-induced HepG2 apoptosis. Apoptosis 2008, January, Luxembourg.

16. Foltopoulou P.F., Tsiftsoglou A.S., Bonovolias I.D., and Papadopoulou L.C. (2008). Targeted delivery of recombinant fusion human mitochondrial TAT-Sco2-HA protein into mammalian cells via PTD technology: a protein therapy approach for metabolic disorders. Joint Conference of the 33rd FEBS Congress/11th IUBMB Conference, FEBS JOURNAL, Vol: 275, pp: 195-195, JUN 28-JUL 03, Athens, GREECE

17. Papadopoulou L.C, Foltopoulou P.F., Bonovolias I.D., and Tsiftsoglou A.S. (2009). Targeted

Intracellular Delivery of Human Recombinant Proteins into Mammalian Cells / Tissues as a potentially Protein Therapeutic Approach: The case of Mitochondrial Sco2 protein. 6th International Conference on Nanosciences & Nanotechnologies, 13-15 July, Thessaloniki, Greece, p.53

18. Tsiftsoglou A.S., Bonovolias I.D., and Papadopoulou L.C. (2009). Imatinib suppresses the expression of Mitochondrial COX assembly SCO2 gene in human K-562 BCR-ABL (+) CML cells. 38th Annual Scientific Meeting of the ISEH-Society-for-Hematology-and-Stem-Cells, September 9-12, Athens, Greece EXPERIMENTAL HEMATOLOGY Vol: 37(9) pp: S47-S48

19. Papadopoulou L.C., Foltopoulou P.F. and Tsiftsoglou A.S. (2010). Intracellular Delivery of

Recombinant Human Proteins into Mammalian cells as a Potential Therapeutic Approach. Proceedings (M622) of the 10th EUROBIC, June 22-26, Thessaloniki, Greece

20. Tsiftsoglou A.S., Bonovolias I.D., and Papadopoulou L.C. (2010). The p53/Sco2/COX interactive pathway in mitochondria as a novel target for Imatinib in human K-562 Bcr-Abl(+) cells. In MODERN TRENDS IN HUMAN LEUKEMIA & CANCER. XVIII. Wilsede meeting, June 19-23, Germany

21. Gavriilidis G., Papadopoulou L.C., Tsiftsoglou A.S. (2012) Cloning, expression, purification and

biological activity of Human Soluble Stem Cell Factor (hs SCF) in E. Coli cells. 64th Congress of the Hellenic Society of Biochemistry and Molecular Biology, December 2013, Athens, Greece

22. Papadopoulou LC. (2013) Protein transduction via PTD technology as a therapeutic approach of mitochondrial disorders. 2nd international conference and Exhibition on neurology & Therapeutics. June 17-19, Hilton Chicago/Northbrook, Chicago, USA

23. Papagiannopoulou D., Kaiafas G., Papadopoulou L. (2014) In vitro and in vivo evaluation of

TC-99m radiolabeled cell penetrating TAT-L-Sco2-HA mitochondrial protein. 65ο Panhellenic Conference of HSBMB, 28-30 November, Thessaloniki.

24. Tsoukas E., Kydonaki T.E., Psomas G., Papagiannopoulou D, Papadopoulou LC. Cytotoxicity of Re/Enrofloxacin complex in two different cancer cell lines (2016) 9ο Panhellenic Congress of Pharmacology, 20-22 Μay, Electra Palace, Thessaloniki.

25. Papadopoulou L.C., Ingendoh-Tsakmakidis A, Mpoutoureli CN, Tzikalou LD, Gavriilidis GI,

Kaiafas GC, Ntaska AT, Spyridou ED, Zaverda C.G, Nentoudi K.A., Vlachaki E, Samiotaki M, Panayotou G, Tsiftsoglou AS. (2017) Production and transduction of human recombinant TAT-β-globin chain into K562 model system for thalassemias.14th International Conference on Thalassemia and Other Haemoglobinopathies & 16th TIF Conference for Patients and Parents. 17-19 November, Thessaloniki, Greece.

26. Mavridou D.D., Gavriilidis G.I., L Papadopoulou L.C. (2018) Effects of imatinib and dichloroacetate acid on cellular bioenergetics of Chronic Lymphocytic Leukemia cells. Short Oral Presentation at the 10th Congress of the Hellenic Society for Basic and Clinical Pharmacology, 25-27 May, Ioannina, Greece.

27. Miliotou A.N., Laspa, D.G., Papadopoulou L.C. (2018) Cloning and expression of recombinant

human α-globin through PTD technology: Study of its intracellular transduction in K562 proerythroid cell culture. Poster presentation at the 10th Congress of the Hellenic Society for Basic and Clinical Pharmacology, 25-27 May, Ioannina, Greece.

28. Miliotou A.N., Pappas I.S., Vizirianakis I.S., Papadopoulou L.C. (2018) Development of in vitro transcribed SCO2 mRNA as novel therapeutic approach in a mitochondrial disorder, due to SCO2 mutations. Short Oral Presentation at the 69th Panhellenic Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB), 23-25 November, Larisa, Greece.

29. Miliotou N. Androulla, Pappas S. Ioannis, Vizirianakis S. Ioannis and Papadopoulou C. Lefkothea. (2019) “IVT-mRNA conjugated to a protein transduction domain, as a novel gene delivery platform for protein replacement therapy”. 7th mRNA Health Conference, 11-12 November, Berlin, Germany

30. Miliotou N. Androulla, Pappas S. Ioannis, Vizirianakis S. Ioannis and Papadopoulou C. Lefkothea. (2019) A novel intracellular delivery technology for in vitro transcribed (IVT)-mRNAs. 70th Panhellenic Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB), November 28 –December 1, Athens, Greece.

31. Maria G. Kakafika*, Areti A. Lyta*, George I. Gavriilidis, Ioannis S. Pappas, Ioannis S. Vizirianakis, Asterios S. Tsiftsoglou, Lefkothea C. Papadopoulou (2019) «Assessment of cellular bioenergetics in human K-562 erythroleukemia cells and HCT116 colorectal cells treated with Imatinib mesylate and/or Dichloroacetate». 70th Panhellenic Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB), November 28 –December 1, Athens, Greece.